|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-4-9
|
|
pubmed:abstractText |
This study examined the effectiveness of early and prolonged mu4D5 (the murine form of trastuzumab/Herceptin) treatment in transgenic mice that overexpress human HER2 (huHER2), under the murine mammary tumor virus promoter, as a model of huHER2-overexpressing breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/RNA,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AsghariVidaV,
pubmed-author:EricksonSharonS,
pubmed-author:FinkleDavidD,
pubmed-author:GhaboosiNazliN,
pubmed-author:HollingsheadPhilipP,
pubmed-author:KlossJessicaJ,
pubmed-author:KoeppenHartmutH,
pubmed-author:MaiElaineE,
pubmed-author:QuanZhi RickyZR,
pubmed-author:SchwallRalphR,
pubmed-author:WongWai LeeWL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2499-511
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15073130-Animals,
pubmed-meshheading:15073130-Antibodies, Monoclonal,
pubmed-meshheading:15073130-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15073130-Base Sequence,
pubmed-meshheading:15073130-Disease Progression,
pubmed-meshheading:15073130-Down-Regulation,
pubmed-meshheading:15073130-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15073130-Female,
pubmed-meshheading:15073130-Humans,
pubmed-meshheading:15073130-Immunohistochemistry,
pubmed-meshheading:15073130-In Situ Hybridization, Fluorescence,
pubmed-meshheading:15073130-Lung Neoplasms,
pubmed-meshheading:15073130-Mammary Neoplasms, Animal,
pubmed-meshheading:15073130-Mammary Tumor Virus, Mouse,
pubmed-meshheading:15073130-Mice,
pubmed-meshheading:15073130-Mice, Transgenic,
pubmed-meshheading:15073130-Models, Genetic,
pubmed-meshheading:15073130-Molecular Sequence Data,
pubmed-meshheading:15073130-Neoplasm Metastasis,
pubmed-meshheading:15073130-Neoplasms, Experimental,
pubmed-meshheading:15073130-Promoter Regions, Genetic,
pubmed-meshheading:15073130-RNA,
pubmed-meshheading:15073130-RNA, Messenger,
pubmed-meshheading:15073130-Receptor, erbB-2,
pubmed-meshheading:15073130-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15073130-Time Factors,
pubmed-meshheading:15073130-Transgenes
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
|
|
pubmed:affiliation |
Department of Physiology, Genentech, Inc., South San Francisco, California 94080, USA.
|
|
pubmed:publicationType |
Journal Article
|
